Your browser of choice has not been tested for use with If you have issues, please download one of the browsers listed here.

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Jazz Pharma Plc FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD DUBLIN L2 D04 IRL P: 353-1634-7800 F: 353-163-4785


Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.

Key Statistics


Market Capitalization, $K 8,947,538
Shares Outstanding, K 59,950
Annual Sales, $ 1,488 M
Annual Net Income, $ 396,830 K
Last Quarter Sales, $ 411,860 K
Last Quarter Net Income, $ 63,530 K
36-Month Beta 0.98
% of Insider Shareholders 4.30%
% of Institutional Shareholders 91.26%


1-Year Total Return 19.51%
3-Year Total Return -15.29%
5-Year Total Return 159.29%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 3.22 on 11/07/17
Next Earnings Date 02/27/18
Earnings Per Share ttm 7.97
EPS Growth vs. Prev Qtr 70.35%
EPS Growth vs. Prev Year 35.65%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

JAZZ Ratios

Price/Earnings ttm 18.78
Price/Earnings forward 12.94
Price/Earnings to Growth 0.80
Return on Equity % 22.92
Return on Assets % 10.07
Net Margin % 43.42
Debt/Equity 0.63
Price/Sales 5.77
Price/Cash Flow 16.78
Price/Book 3.63
Book Value/Share 41.09
Interest Coverage 4.39
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.